Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Cancer
Published in: Journal of Gastrointestinal Cancer 4/2019

01-12-2019 | Lymphoma | Case Report

Monomorphic Epitheliotropic Intestinal T cell Lymphoma: a Rare Cause of Chronic Diarrhea

Authors: Ronald Samuel, Timothy Krill, Shehzad Merwat

Published in: Journal of Gastrointestinal Cancer | Issue 4/2019

Login to get access

Excerpt

Chronic diarrhea is a frustrating and sometimes difficult diagnosis for patients and physicians alike. The etiology is vast and variable. Periodically, numerous studies are required to arrive at a diagnosis. Monomorphic epitheliotropic intestinal T cell lymphoma (MEITL) is a rare and aggressive form of lymphoma that can occur throughout the gastrointestinal tract. Symptoms are variable but can include fever, abdominal pain, weight loss, diarrhea, obstruction, and perforation [1]. Prognosis is poor, and treatment usually consists of surgery, chemotherapy, or stem cell transplantation. We present a case of voluminous chronic diarrhea in an African-American male with associated weight loss due to MEITL. …
Literature
1.
Tan SY, Chuang SS, Tang T, Tan L, Ko YH, Chuah KL, et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. Leukemia. 2013;27(8):1688–96.CrossRef
2.
van de Water JM, Cillessen SA, Visser OJ, Verbeek WH, Meijer CJ, Mulder CJ. Enteropathy associated T-cell lymphoma and its precursor lesions. Best Pract Res Clin Gastroenterol. 2010;24(1):43–56.CrossRef
3.
Deleeuw RJ, Zettl A, Klinker E, et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology. 2007;132(5):1902–11.CrossRef
4.
Chan JK, Chan AC, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol. 2011;35(10):1557–69.CrossRef
5.
Ko YH, Karnan S, Kim KM, Park CK, Kang ES, Kim YH, et al. Enteropathy-associated T-cell lymphoma--a clinicopathologic and array comparative genomic hybridization study. Hum Pathol. 2010;41(9):1231–7.CrossRef
6.
Sun J, Lu Z, Yang D, Chen J. Primary intestinal T-cell and NK-cell lymphomas: a clinicopathological and molecular study from China focused on type II enteropathy-associated T-cell lymphoma and primary intestinal NK-cell lymphoma. Mod Pathol. 2011;24(7):983–92.CrossRef
7.
Ishibashi H, Nimura S, Kayashima Y, Takamatsu Y, Aoyagi K, Harada N, et al. Multiple lesions of gastrointestinal tract invasion by monomorphic epitheliotropic intestinal T-cell lymphoma, accompanied by duodenal and intestinal enteropathy-like lesions and microscopic lymphocytic proctocolitis: a case series. Diagn Pathol. 2016;11(1):66.CrossRef
8.
Kim JB, Kim SH, Cho YK, Ahn SB, Jo YJ, Park YS, et al. A case of colon perforation due to enteropathy-associated T-cell lymphoma. World J Gastroenterol. 2013;19(11):1841–4.CrossRef
9.
Schmitt-Gräff A, Hummel M, Zemlin M, Schneider T, Ullrich R, Heise W, et al. Intestinal T-cell lymphoma: a reassessment of cytomorphological and phenotypic features in relation to patterns of small bowel remodelling. Virchows Arch. 1996;429(1):27–36.CrossRef
10.
Gentille C, Qin Q, Barbieri A, Ravi PS, Iyer S. Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. Ecancermedicalscience. 2017;11:771.CrossRef
11.
Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118(1):148–55.CrossRef
12.
Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18(4):795–803.CrossRef
Metadata
Title
Monomorphic Epitheliotropic Intestinal T cell Lymphoma: a Rare Cause of Chronic Diarrhea
Authors
Ronald Samuel
Timothy Krill
Shehzad Merwat
Publication date
01-12-2019
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 4/2019
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00210-3

Other articles of this Issue 4/2019

Journal of Gastrointestinal Cancer 4/2019 Go to the issue

Case Report

Late-Onset Lung Metastasis in Rectum Cancer Can Be Confused with Primary Lung Cancer; a Case Report and Literature Review

Case Report

“Pure” High-Grade Large Cell Neuroendocrine Carcinoma Arising from Low- and High-Grade Dysplasia of the Gallbladder: Case Report and Review of the Literature

Original Research

Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma

Case Report

Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response

Case Report

Undifferentiated Embryonal Sarcoma of the Liver: a Great Masquerader

Original Research

Epidemiology of Colorectal Cancer and the Risk Factors in Kermanshah Province-Iran 2009–2014
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits